Medical Marijuana Market Summary

• The Medical Marijuana Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
• Key medical marijuana companies, such as Harmony Biosciences, Cardiol Therapeutics, Avecho Biotechnology Ltd., Neurotech International, Avicanna, Incannex Healthcare, Avicanna Inc., BRC Therapeutics, SciSparc, Botanix SB Inc., Argent BioPharma, ANANDA Scientific, Inc., InnoCan Pharma, Canfite BioPharma Ltd., Artelo Biosciences, InMed Pharmaceuticals, MIRA Pharmaceuticals, Virpax Pharmaceuticals, CNBX Pharmaceuticals, Revive Therapeutics, Aphios Corporation, Andira Pharmaceuticals, and others, are evaluating new medical marijuana drugs to improve the treatment landscape.
• Promising pipeline medical marijuana therapies, such as ZYN-002, CardiolRx, Cannabidiol soft-gel capsule, NTI164, AVCN319301b, IHL-42X, AVCN-319301a, BRC-001, IHL-675A, SCI-110, BTX 1801, BTX 1503, CannEpil, Nantheia A1002N5S, Nantheia™ ATL5, LPT-CBD, Research Program, ART 12.11, INM-901, INM089, MIRA-55, NobrXiol, MLN-33, RCC-33, PRST-33, PLP-33, BRST-33, Cannabidiol, APH-1504, AND-259, AND-254, Silvanex, NP-01, and others, are under different phases of medical marijuana clinical trials.

Request for Unlocking the CAGR of Medical Marijuana Treatment Market

Key Factors Driving the Medical Marijuana Market Growth

• Increasing Legalization and Policy Support

Expanding legalization across various countries and U.S. states has boosted accessibility and regulatory clarity for medical marijuana use.

• Rising Burden of Chronic and Neurological Disorders

The growing prevalence of chronic pain, cancer, epilepsy, multiple sclerosis, and PTSD is driving demand for effective cannabis-based therapeutic options.

• Growing Clinical Evidence and Physician Acceptance

Continuous clinical research and positive patient outcomes are improving medical community confidence in cannabis-based treatments.

• Increasing Public Awareness and Acceptance

Rising awareness about the therapeutic potential of cannabinoids for pain management, anxiety, and inflammation is fostering wider adoption.

DelveInsight's "Medical Marijuana Treatment Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Medical Marijuana, historical and forecasted epidemiology as well as the Medical Marijuana market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Medical Marijuana Treatment Market report provides current treatment practices, emerging drugs, Medical Marijuana market share of the individual therapies, current and forecasted Medical Marijuana market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Medical Marijuana treatment market practice/algorithm, Medical Marijuana Market Drivers, market barriers and Medical Marijuana unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

Medical Marijuana Treatment Market

Medical marijuana, also known as medical cannabis, refers to cannabis and its active compounds, primarily cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD), used under medical supervision to help manage certain health conditions and symptoms. Depending on the formulation and condition, medical marijuana may be used to alleviate chronic pain, chemotherapy-related nausea and vomiting, muscle spasticity, and other symptoms. It is available in various forms, including oils, capsules, tablets, oral sprays, and dried cannabis, although approved products and permitted uses vary by country and region. Unlike recreational cannabis, medical marijuana is intended specifically for therapeutic purposes and is generally subject to medical and regulatory oversight.

Medical Marijuana Diagnosis

Medical marijuana diagnosis involves the evaluation and assessment of patients to determine their eligibility for using marijuana as a therapeutic treatment. It is a process conducted by healthcare professionals, typically doctors or specialists, who specialize in understanding the potential benefits and risks associated with medical cannabis. This segment of the report covers the detailed diagnostic methods or tests for Medical Marijuana.

Medical Marijuana Treatment

Medical marijuana treatment refers to the therapeutic use of cannabis or its derivatives to alleviate symptoms and manage various medical conditions. With its active compounds known as cannabinoids, such as THC and CBD, medical marijuana has shown potential in providing relief for patients dealing with chronic pain, nausea, muscle spasms, and other debilitating symptoms. The cannabinoids interact with the body's endocannabinoid system, which plays a crucial role in regulating various physiological functions. Medical marijuana has been used to address conditions such as multiple sclerosis, epilepsy, cancer-related side effects, and post-traumatic stress disorder (PTSD). The treatment can take various forms, including smoking or vaporizing the plant, consuming edibles or tinctures, or applying topical creams. It covers the details of conventional and current medical therapies available in the Medical Marijuana market for the treatment of the condition. It also provides Medical Marijuana treatment algorithms and guidelines in the United States, Europe, and Japan.

Medical Marijuana Epidemiology 

The Medical Marijuana epidemiology division provide insights about historical and current Medical Marijuana patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Medical Marijuana Prevalence Scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

Medical Marijuana Drugs Analysis

The drug chapter segment of the Medical Marijuana drugs market report encloses the detailed analysis of Medical Marijuana marketed drugs and late-stage (Phase-III and Phase-II) Medical Marijuana pipeline drugs. It also helps to understand the Medical Marijuana clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Medical Marijuana Marketed Drugs

Exilby: Vertanical

VER-01 (Exilby), developed by Vertanical, is a standardized full-spectrum Cannabis sativa extract that has emerged as Europe’s first approved medical cannabis-based treatment for chronic low back pain with a radicular (neuropathic) component. The therapy received marketing authorization in Germany in June 2026 after Phase III trials demonstrated significant reductions in pain, improvements in physical functioning and sleep, favorable tolerability, and no signs of dependence or withdrawal. Positioned as a first-in-class non-opioid analgesic, VER-01 provides a pharmaceutical-grade, standardized cannabinoid formulation as a potential alternative to opioids for chronic pain management. A pivotal Phase III trial evaluating the therapy in the United States is currently underway.

Syndros: Benuvia Therapeutics

Syndros is an orally administered liquid formulation containing dronabinol, a synthetic form of THC and a pharmaceutical cannabinoid. Dronabinol exerts complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been identified in neural tissues and are believed to contribute to the pharmacological effects of dronabinol. Syndros is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, as well as nausea and vomiting related to cancer chemotherapy in patients who have not responded adequately to conventional antiemetic therapies. Available as an oral solution, Syndros is the first and only FDA-approved dronabinol formulation in liquid oral form.

Medical Marijuana Emerging Drugs

CardiolRx: Cardiol Therapeutics

CardiolRx™ is an investigational, cannabidiol (CBD) oral solution containing virtually no THC, developed to pharmaceutical cGMP standards for purity, consistency, and stability. Unlike approved medical marijuana products, CardiolRx is a CBD-only cannabinoid therapy being evaluated for inflammatory cardiovascular diseases, including recurrent pericarditis and acute myocarditis. The drug exerts anti-inflammatory and anti-fibrotic effects by inhibiting activation of the NLRP3 inflammasome and related inflammatory signaling pathways implicated in cardiac injury and fibrosis. CardiolRx has demonstrated a favorable safety profile in Phase I studies, holds FDA and EMA orphan drug designations for select indications, and is currently in Phase III clinical development for recurrent pericarditis and Phase II for acute myocarditis.

MRX2: Ananda Pharma

MRX2 is an investigational, CBD-only cannabinoid medicine being evaluated in large-scale, randomized, controlled trials for treatment-resistant epilepsies. It is being studied across a broad range of seizure types in children and adults to determine its safety and effectiveness in reducing seizures, as well as its potential impact on cognition, behavior, sleep, quality of life, and stress. Currently, the drug is in Phase III stage of its clinical development for the treatment of Refractory Epilepsies.

Read more about Medical Marijuana Competitive Intelligence Analysis 2026

Recent Developments in the Medical Marijuana Treatment Space

• In June 2026, PleoPharma, Inc. announced that the first patient has been dosed in CAN-004, a Phase III clinical trial evaluating PP-01, an investigational medication intended for the mitigation of cannabis withdrawal symptoms in adults with cannabis use disorder (CUD).
• In April 2026, Cardiol Therapeutics Inc. announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States, with the planned activation of up to seven additional clinical centers. Patient enrollment in MAVERIC surpassed the 50% threshold in early January and has now reached 75%. Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from additional clinical sites.
• In April 2026, BRC Therapeutics announced that the company can proceed with a Phase I study to further establish the safety of BRC-002 in healthy volunteers. BRC-002 is a first-in-class investigational product aiming to address pain and other symptoms of Complex Regional Pain Syndrome (CRPS). The US Food and Drug Administration (FDA) granted Orphan Drug Designation for the treatment of CRPS to BRC-002. BRC-002 is a multimodal botanical drug composed of prescription-grade cannabinoids at defined and proprietary ratios.
• In January 2026, IGC Pharma, Inc. announced that it has entered into a Subscription Agreement with a group of investors for the purchase and sale of an aggregate of 779,997 shares of common stock in a registered direct offering, at a purchase price of USD 0.30 per share. The Company intends to use the net proceeds for working capital and general corporate purposes, including continued funding of its Phase II clinical development program for IGC-AD1.
• In June 2025, Avata Biosciences Holdings Ltd announced that it has signed a co-development and licensing agreement with Oceanus Bio, Inc. for the exclusive rights to AVAT-021 and AVAT-022 in Japan and Asia, except in China and India. The agreement comprised of USD 95m in co-development contributions, regulatory and sales milestone payments to Avata.
• In May 2025, Incannex Healthcare Inc. announced that the Phase III component of the RePOSA clinical trial will proceed. The US Food and Drug Administration (FDA) previously reviewed and authorized the protocol to proceed under the Company’s Investigational New Drug (IND) application. The study will evaluate the efficacy and safety of IHL-42X, Incannex’s lead asset for the treatment of obstructive sleep apnea (OSA)—a condition affecting an estimated one billion people globally with no approved oral pharmaceutical therapy.
• In March 2025, Argent BioPharma confirmed that pharmaceutical manufacturer ECCPharm will take on full production and release responsibilities for Argent’s emerging cannabinoid therapies under a strategic partnership between the two companies. The agreement will ensure the CannEpil and CogniCann treatments are available under early patient access programs in key European countries including Ireland, the UK and Germany. Argent will retain ownership of all current and future research and development, as well as intellectual property rights, under the partnership.
  

Medical Marijuana Market Outlook

The Medical Marijuana market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Medical Marijuana market trends by analyzing the impact of current therapies on the market, Medical Marijuana unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Medical Marijuana market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

"According to DelveInsight, the Medical Marijuana Treatment Market in 7MM is expected to change in the study period 2022-2036."

Medical Marijuana Drugs Uptake

This section focuses on the rate of uptake of the potential Medical Marijuana drugs recently launched in the Medical Marijuana market or expected to get launched in the market during the study period 2022-2036. The analysis covers Medical Marijuana market uptake by drugs; patient uptake by therapies; and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new Medical Marijuana drugs and allow the comparison of the drugs on the basis of Medical Marijuana market share and size which again will be useful in investigating factors important in Medical Marijuana drug market uptake and in making financial and regulatory decisions.

Medical Marijuana Pipeline Development Activities

The Medical Marijuana pipeline segment provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Medical Marijuana companies involved in developing targeted therapeutics. The Medical Marijuana pipeline covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Medical Marijuana emerging therapies.

Learn more about Medical Marijuana Cannabidiol Pipeline Insight, 2023

Medical Marijuana Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a Medical Marijuana Drug Market Report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on Medical Marijuana

To keep up with current market trends, we take KOLs and SME's opinion working in Medical Marijuana domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Medical Marijuana market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the Medical Marijuana unmet needs.

Medical Marijuana Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Medical Marijuana Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Medical Marijuana Market Report

• The Medical Marijuana Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Medical Marijuana Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Medical Marijuana Treatment landscape.
• A detailed review of the Medical Marijuana Therapeutics Market, historical and forecasted Medical Marijuana Treatment Market Size, Medical Marijuana Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Medical Marijuana Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Medical Marijuana Drugs Market.

Medical Marijuana Market Report Insights

• Medical Marijuana Patient Population Forecast
• Medical Marijuana Therapeutics Market Size
• Medical Marijuana Pipeline Drugs Analysis
• Medical Marijuana Market Size and Trends
• Medical Marijuana Therapeutics Market Opportunity (Current and Forecasted)

Medical Marijuana Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Medical Marijuana Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Medical Marijuana Treatment Addressable Market (TAM)
• Medical Marijuana Competitive Landscape
• Medical Marijuana Major Companies Insights
• Medical Marijuana Price Trends and Analogue Assessment
• Medical Marijuana Therapies Drug Adoption/Uptake
• Medical Marijuana Therapies Peak Patient Share Analysis

Medical Marijuana Market Report Assessment

• Medical Marijuana Current Treatment Practices
• Medical Marijuana Unmet Needs
• Medical Marijuana Clinical Development Analysis
• Medical Marijuana Emerging Drugs Product Profiles
• Medical Marijuana Market Attractiveness
• Medical Marijuana Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Medical Marijuana Treatment Market Report

Medical Marijuana Therapeutics Market Insights

• What was the Medical Marijuana Treatment Market Size, the Medical Marijuana Market Size by therapies, Medical Marijuana Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Medical Marijuana?
• What are the disease risks, burdens, and unmet needs of Medical Marijuana? 
• What will be the growth opportunities across the 7MM concerning the patient population with Medical Marijuana?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Medical Marijuana? What are the current guidelines for treating Medical Marijuana in the US, Europe, and Japan?

Reasons to Buy the Medical Marijuana Therapeutics Market Report

• The Medical Marijuana Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Medical Marijuana Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Medical Marijuana Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Medical Marijuana Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Medical Marijuana Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Medical Marijuana Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Access Exclusive Data Now! Click here to Read More about the Related Articles

• Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing
• Medical Marijuana: Is it a blessing in disguise or a curse for humanity?
• What can be the scope of Medical Marijuana?
• Can Alzheimer's be cured with Marijuana?
• Marijuana as a treatment approach
• Medical Marijuana Newsletter
• Latest DelveInsight Blogs